Biovest approved to expand BiovaxID trial for non-Hodgkin's lymphoma in Russia

By Lisa Kerner

Charlotte, N.C., July 18 - Biovest International, Inc. said it received regulatory approval from the Russian Ministry of Health and Social Development to recruit patients for its ongoing phase 3 clinical trial of BiovaxID for the treatment of indolent follicular non-Hodgkin's lymphoma.

During the next 18 months, Biovest plans to recruit up to 175 patients from 14 clinical sites located throughout the Russian Federation.

"With the addition of these sites in the Russian Federation, and with other initiatives underway in the United States, we feel confident that we are on track to complete enrollment as planned," chairman and chief executive officer Steve Ankian said in a company news release.

"In anticipation of the influx of clinical samples from these sites, we have already completed the first phase of the expansion of our vaccine manufacturing facility in Worcester, Mass."

Non-Hodgkin's lymphoma is a cancer of the lymphatic system that affects 65,000 new patients each year in the United States.

Based in Worcester, Mass., biologics manufacturer Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.